Psoriatic Arthritis — Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
Citation(s)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs